Kevin D Lance1, Samuel D Good2, Thaís S Mendes2, Mynna Ishikiriyama2, Patrick Chew3, Laurel S Estes3, Kazuhito Yamada4, Sri Mudumba5, Robert B Bhisitkul2, Tejal A Desai6. 1. University of California at Berkeley-University of California, San Francisco Bioengineering Graduate Program, San Francisco, California, United States. 2. Department of Ophthalmology, University of California, San Francisco, San Francisco, California, United States. 3. Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, California, United States. 4. Pharmaceutical Development Group, Pharmaceutical Development Center, Santen Pharmaceutical Co., Ltd., Nara, Japan. 5. Pharmaceutical Development, Santen, Inc., Emeryville, California, United States. 6. University of California at Berkeley-University of California, San Francisco Bioengineering Graduate Program, San Francisco, California, United States 3Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Fra.
Abstract
PURPOSE: We created implantable intraocular devices capable of constant and continuous rapamycin release on the scale of months to years. METHODS: Polycaprolactone (PCL) thin films were used to encapsulate rapamycin to create implantable and biodegradable intraocular devices. Different film devices were studied by modifying the size, thickness, and porosity of the PCL films. RESULTS: In vitro release of rapamycin was observed to be constant (zero-order) through 14 weeks of study. Release rates were tunable by altering PCL film porosity and thickness. In vivo release of rapamycin was observed out through 16 weeks with concentrations in the retina-choroid in the therapeutic range. Rapamycin concentration in the blood was below the lower limit of quantification. The drug remaining in the device was chemically stable in vitro and in vivo, and was sufficient to last for upwards of 2 years of total release. The mechanism of release is related to the dissolution kinetics of crystalline rapamycin. CONCLUSIONS: Microporous PCL thin film devices demonstrate good ocular compatibility and the ability to release rapamycin locally to the eye over the course of many weeks.
PURPOSE: We created implantable intraocular devices capable of constant and continuous rapamycin release on the scale of months to years. METHODS:Polycaprolactone (PCL) thin films were used to encapsulate rapamycin to create implantable and biodegradable intraocular devices. Different film devices were studied by modifying the size, thickness, and porosity of the PCL films. RESULTS: In vitro release of rapamycin was observed to be constant (zero-order) through 14 weeks of study. Release rates were tunable by altering PCL film porosity and thickness. In vivo release of rapamycin was observed out through 16 weeks with concentrations in the retina-choroid in the therapeutic range. Rapamycin concentration in the blood was below the lower limit of quantification. The drug remaining in the device was chemically stable in vitro and in vivo, and was sufficient to last for upwards of 2 years of total release. The mechanism of release is related to the dissolution kinetics of crystalline rapamycin. CONCLUSIONS: Microporous PCL thin film devices demonstrate good ocular compatibility and the ability to release rapamycin locally to the eye over the course of many weeks.
Authors: Jean Kim; Max Kudisch; Nina Rosa Konichi da Silva; Hiroyuki Asada; Eri Aya-Shibuya; Michele M Bloomer; Sri Mudumba; Robert B Bhisitkul; Tejal A Desai Journal: J Control Release Date: 2017-11-07 Impact factor: 9.776
Authors: Karen E Samy; Yiqi Cao; Jean Kim; Nina Rosa Konichi da Silva; Audrey Phone; Michele M Bloomer; Robert B Bhisitkul; Tejal A Desai Journal: J Ocul Pharmacol Ther Date: 2019-01-07 Impact factor: 2.671
Authors: Erica Schlesinger; Daniel Johengen; Ellen Luecke; Ginger Rothrock; Ian McGowan; Ariane van der Straten; Tejal Desai Journal: Pharm Res Date: 2016-03-14 Impact factor: 4.200
Authors: C Nathaniel Roybal; Gabriel Velez; Marcus A Toral; Stephen H Tsang; Alexander G Bassuk; Vinit B Mahajan Journal: Am J Ophthalmol Date: 2017-12-13 Impact factor: 5.258
Authors: Jean Kim; Max Kudisch; Sri Mudumba; Hiroyuki Asada; Eri Aya-Shibuya; Robert B Bhisitkul; Tejal A Desai Journal: Invest Ophthalmol Vis Sci Date: 2016-08-01 Impact factor: 4.799
Authors: Paulina García-Estrada; Miguel A García-Bon; Edgar J López-Naranjo; Dulce N Basaldúa-Pérez; Arturo Santos; Jose Navarro-Partida Journal: Pharmaceutics Date: 2021-05-12 Impact factor: 6.321